Bioinformatics, biotech and nanotechnology companies seeking venture capital funding may have to look elsewhere, according to speakers at the Silicon Alley Breakfast Club (SABC) meeting held here Thursday.


VCs may spurn bioinformatics, biotech startups - News More Information About
· BioITWorld Expo, Mar. 12-14
· IDC Market Data
Home > News > VCs may spurn bioinformatics, biotech startups



VCs may spurn bioinformatics, biotech startups
By Salvatore Salamone
Bio-IT World
NEW YORK (03/08/02)—Bioinformatics, biotech and nanotechnology companies seeking venture capital funding may have to look elsewhere, according to speakers at the Silicon Alley Breakfast Club (SABC) meeting held here Thursday.

For the last two years, the SABC has focused on the business and funding of dot-com companies. But with the downturn in that market, the emphasis at today's meeting was to look at the hot technologies that are getting the interest of the venture capital (VC) community.

"Science is the new sexy kid on the block," said Anna Copeland Wheatley, executive editor of Innovation, a newsletter published by the Berkley Center for Entrepreneurial Studies, New York University Stern School of Business.

VCs are definitely interested in the biotech market, but the panel of speakers warned that companies should not expect funds to be as readily available as has been the case over the last few years.

The reason: VCs are returning to past, more sound business practices.

The main message conveyed to biotechnology startups at the SABC meeting was that VC funding will not be impossible to get, it is just going to be harder to get.

That means startups can no longer simply have a neat idea or cool technology. The idea or technology has to lead to a revenue-generating business. And, for that reason, VCs will be looking for things like experienced management teams at the helm.

"For all the talk about vision and strategy, what makes a company successful is good management," said Esther Dyson, chairman of the information services company EDventure Holdings Inc. And that is what the VCs are looking for.

Several speakers at the meeting noted that companies with early stage technologies and no real products are not likely to get VC funded.

But there are alternatives.

"VC funding is not the only funding on the planet," said Wheatley. She noted that people just assume that to be the case because of the blitz of VC funding over the last few years.

"There is other money out there," said Wheatley. "There's angel funding and private equity, and government money is available for R&D."

For example, "VCs have funded about 15 nanotechnology companies in the U.S.," said Lawrence Phillips, founder and managing director of Value Acceleration Partners, a crisis consulting and interim management firm. "But the total funding into the 15 companies is about one-tenth the amount of public funding going into nanotechnology at universities."


Salvatore Salamone is the senior technology editor at Bio·IT World and can be reached at Salvatore_Salamone@idg.com.


  
Subscribe        Newsletters       Contact Us    2002 Bio·IT World Privacy Policy

March 08, 2002   

Story index for IDG.Net

Story index2 for IDG.Net

Story index3 for IDG.Net
Related Links:

Story index for IDG.Net

Story index for IDG.Net
News index for IDG.Net
News index for eBusiness World
News index for eCommerce World
News index for TechInformer
E-businessworld Stories
Techinformer Stories
Best IT content




This is a computer-edited content for no-frames display browsers or clawlers.
To see the fully formated content, get a frames-capable browser and surf to http://www.bio-itworld.com/news/030802_report99.html